千红制药：公司原创一类创新药物QHRD106、QHRD107均处于推进临床试验的过程中

Core Viewpoint - The company is actively progressing with its innovative drugs QHRD106 and QHRD107, addressing investor concerns regarding delays in clinical trials [2]. Group 1 - The company responded to investor inquiries about potential major issues causing delays in the clinical trial applications for its innovative drugs [2]. - Both QHRD106 and QHRD107 are currently advancing in their clinical trial processes in an orderly manner [2]. - The company is committed to following the requirements set by the Center for Drug Evaluation (CDE) to ensure the new drug development process is fully supported [2].